Abstract 48P
Background
There is a lack of real-world data on clinicodemographics and management of pts with HER2+ u/mBC from Asia-Pacific. The HER2 REAL (NCT04857619) retrospective study determined the clinical characteristics, treatment practices, and survival outcomes of pts with HER2+ u/mBC from routine clinical care.
Methods
Adult pts diagnosed with HER2+ u/mBC (index date) since wider access to trastuzumab emtansine (via reimbursement or out of pocket) in Jan 2015 (Singapore [SG]), or Jan 2017 (for Hong Kong [HK], Republic of Korea [KR], (Taiwan [TW]), and completing ≥1 line of therapy (LOT) with ≥12 months (mo) follow-up data from index date were enrolled per medical chart review (data cut-off 31 Oct 2022). We present descriptive statistics of available clinicodemographic data from four Asian countries. Some pts were excluded due to insufficient proof of HER2 positivity or not completing ≥1 LOT in the metastatic setting.
Results
Of the 535 pts screened, 502 were analyzed (HK: 92, KR:157, SG:105, TW: 148), with median age ranging from 51-58 yrs; 69.7% (290/416) women were postmenopausal at index date. ECOG was ≤1 in all the pts from KR (62/62), followed by SG (94.4%, 17/18), HK (85.4%, 41/48), and TW (72.7%, 24/33); 99.5% (444/446) of pts had stage IV disease and most had ductal carcinoma (KR: 95.7%, 110/115; HK: 87.7%, 50/57; TW: 85.1%, 86/101; SG: 79.5%, 62/78) at index date. Of the pts with available data, family history of BC was reported by 16.3% (73/447) of pts. SG had the highest proportion of patients with ER+ (57.0%, 49/86) and PR+ (50.6%, 42/83) BC. The median time from the initial BC diagnosis to the index date was the longest for SG (34 [2-183] mo). Of the pts with available data, all from KR (91/91), 93.3% SG (56/60), 89.0% TW (65/73), and 45.1% HK (23/51) had govt/employer-funded insurance Table: 48P
| Characteristics*, n (%) | HK | KR | SG | TW |
| Family history | 19/81 (23.5) | 16/136 (11.8) | 18/90 (20.0) | 20/140 (14.3) |
| Metastasis site | ||||
| Non-visceral only | 17/92 (18.5) | 43/157 (27.4) | 20/105 (19.0) | 14/148 (9.5) |
| Visceral | 67/92 (72.8) | 100/157 (63.7) | 77/105 (73.3) | 109/148 (73.6) |
| CNS | 13/92 (14.1) | 31/157 (19.7) | 12/105 (11.4) | 46/148 (31.1) |
| High-grade tumor at initial diagnosis | 12/25 (48.0) | 26/49 (53.1) | 23/31 (74.2) | 29/70 (41.4) |
| ER+ | 30/68 (44.1) | 53/117 (45.3) | 49/86 (57.0) | 38/80 (47.5) |
| PR+ | 13/66 (19.7) | 37/117 (31.6) | 42/83 (50.6) | 21/80 (26.3) |
| Median time from the initial BC diagnosis to index date, months (range) | 29 (0-222) | 29 (0-177) | 34 (2-183) | 25 (0-99) |
*pts with unavailable/missing data not presented
.Conclusions
This real-world study showed notable differences in pt features across four Asian countries, emphasizing the critical need for tailored treatment and improved healthcare equity.
Clinical trial identification
NCT04857619.
Editorial acknowledgement
Medical writing and editorial support were provided by Dr. Purva Thatai and Dr. Debasri Mukherjee from Fortrea Scientific Pvt Ltd funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
S.C. Lee: Financial Interests, Personal, Advisory Board: Pfizer, Novartis, AstraZeneca, Eli Lilly, MSD, Roche, ACT Genomics, and Roche; Financial Interests, Personal, Research Grant: Pfizer, Eisai, Taiho, ACT Genomics, Bayer, Karyopharm, MSD, Epizyme, and Adagene; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer, Novartis, AstraZeneca, Eli Lilly, MSD, Roche, Sanofi, and Daiichi Sankyo. K.C.R. Ngan: Financial Interests, Personal, Financially compensated role: Novartis, AstraZeneca, Sanofi, Pfizer, ZaiLab, Eisai, Lilly, Fosun Pharma, Roche, Nuance (China), Bristol Myers Squibb, Astellas, and Merck, Sharp & Dohme, and Gilead . S. Im: Financial Interests, Personal, Research Grant: AstraZeneca, Daewoong Pharm, Eisai, Roche, and Pfizer; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Eisai, GSK, Hanmi, Lilly, MSD, Idience, Novartis, Roche, and Pfizer; Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GSK, Hanmi, Lilly, MSD, Novartis, Pfizer Inc., and Roche/Genentech. R. Hui: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, Eisai, Eli Lilly, Janssen, Merck Sereno, MSD, Novartis, Oncosec, Pfizer, Roche, Seagen, Takeda, Zai Lab; Financial Interests, Personal, Invited Speaker: AstraZeneca, Eli Lilly, Janssen, MSD, Novartis; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS, Corvus, Eisai, Eli Lilly, Janssen, MSD, Novartis, Oncosec, Roche, Seagen. C. Huang: Financial Interests, Personal and Institutional, Research Grant: from AstraZeneca, Daiichi Sankyo, Novartis, EirGenix, Eli Lilly, MSD, Pfizer, Roche, Gilead; Financial Interests, Personal, Research Grant: from OBI Pharma, Seagen, Aston Sci. T. Tung: Financial Interests, Personal, Full or part-time Employment: AstreZeneca. All other authors have declared no conflicts of interest.